Skip to Main Content

Author Details

Yael P Mosse
Perelman School of Medicine at the University of Pennsylvania
2002
78
43
PMIDPaper TitleJournal TitlePublished Year
37073762Lorlatinib use in an infant with thalamic ALK-positive histiocytosis.Pediatr Blood Cancer2023
37147298Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.Nat Commun2023
37012551Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.Nat Med2023
36381237Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma.Cancer Res Commun2022
36108156Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma.Cancer Discov2022
34028986A safety and feasibility trial of <sup>131</sup> I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study.Pediatr Blood Cancer2021
33823167Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1.Transplant Cell Ther2021
33568345Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912).Clin Cancer Res2021
33674381Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation.Proc Natl Acad Sci U S A2021
33619171The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models.Clin Cancer Res2021
33509943Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers.Cancer Res2021
34536944Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.Eur J Cancer2021
34250393Image-Guided Biopsy for Relapsed Neuroblastoma: Focus on Safety, Adequacy for Genetic Sequencing, and Correlation of Tumor Cell Percent With Quantitative Lesion MIBG Uptake.JCO Precis Oncol2021
34270348Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.J Clin Oncol2021
34088831Venetoclax-based Rational Combinations are Effective in Models of <i>MYCN</i>-amplified Neuroblastoma.Mol Cancer Ther2021
33095287Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212).Cancer Chemother Pharmacol2020
31975571Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report.Pediatr Blood Cancer2020
33049203Advances and Challenges in Pediatric and Childhood Cancers.Cancer Cell2020
31133068Clinical utility of custom-designed NGS panel testing in pediatric tumors.Genome Med2019
31693904Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design.Cell Rep2019
31614113Thrown for a Loop: Awakening BORIS to Evade ALK Inhibition Therapy.Cancer Cell2019
30867324An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma.Sci Transl Med2019
30777875A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921).Clin Cancer Res2019
30738983Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma.Int J Radiat Oncol Biol Phys2019
30793172Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal Neuroblastoma.J Natl Cancer Inst2019
30093449Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.Clin Cancer Res2018
28032129First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium.Cancer Chemother Pharmacol2017
28674118Retinoblastoma and Neuroblastoma Predisposition and Surveillance.Clin Cancer Res2017
28787259Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.J Clin Oncol2017
27986745Dual <i>ALK</i> and <i>CDK4/6</i> Inhibition Demonstrates Synergy against Neuroblastoma.Clin Cancer Res2017
26884555Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.J Clin Oncol2016
26438783Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.Clin Cancer Res2016
26503946Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies.Clin Cancer Res2016
26554404The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.Cancer Discov2016
27997549Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.PLoS Genet2016
26859456Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.Cancer Cell2016
25602966Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma.Br J Cancer2015
24038992Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project.Pediatr Blood Cancer2014
25517749ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.Cancer Cell2014
25133137Dielectrophoretic capture and genetic analysis of single neuroblastoma tumor cells.Front Oncol2014
24347462Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621).Pediatr Blood Cancer2014
23334666The genetic landscape of high-risk neuroblastoma.Nat Genet2013
23598171Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.Lancet Oncol2013
22350409Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.Cancer Res2012
22988055Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study.Clin Cancer Res2012
22585002Targeting ALK in neuroblastoma--preclinical and clinical advancements.Nat Rev Clin Oncol2012
22266870Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.Oncogene2012
22421195Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.Clin Cancer Res2012
21124317Integrative genomics identifies LMO1 as a neuroblastoma oncogene.Nature2011
22072639Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.Sci Transl Med2011
  • 1 - 50 of 78

Recommended Authors

David Pauck
German Cancer Research Center (DKFZ)
Career Start Year 2017
Number of shared co-authors 2
Sebastian Brabetz
Hopp Children's Cancer Center Heidelberg (KiTZ)
Career Start Year 2016
Number of shared co-authors 17
Noah E Berlow
Children's Cancer Therapy Development Institute
Career Start Year 2011
Number of shared co-authors 2
Amanda L Christie
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 4
Jason Saliba
Washington University in St Louis School of Medicine
Career Start Year 2010
Number of shared co-authors 4
Carl Koschmann
University of Michigan-Ann Arbor
Career Start Year 2010
Number of shared co-authors 18
Daniela S Gerhard
National Cancer Institute
Career Start Year 2009
Number of shared co-authors 27
Adrian M Dubuc
Dana-Farber Cancer Institute
Career Start Year 2008
Number of shared co-authors 21
Yana Pikman
Dana Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 2
Matthias Fischer
University Children's Hospital of Cologne
Career Start Year 2003
Number of shared co-authors 14
Amy Smith
Arnold Palmer Hospital for Children
Career Start Year 2003
Number of shared co-authors 16
Christopher C Porter
Emory University School of Medicine
Career Start Year 2003
Number of shared co-authors 6
Michelle J Henderson
Children's Cancer Institute, Lowy Cancer Research Centre
Career Start Year 2002
Number of shared co-authors 16
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Career Start Year 2002
Number of shared co-authors 4
Brent A Orr
St. Jude Children's Research Hospital
Career Start Year 2000
Number of shared co-authors 12
Till Milde
Hopp Children's Cancer Center Heidelberg (KiTZ)
Career Start Year 1998
Number of shared co-authors 21
Anthony J Iafrate
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 10
Rajeev Vibhakar
Center for Cancer and Blood Disorders, Children's Hospital Colorado.
Career Start Year 1997
Number of shared co-authors 15
Qing-Rong Chen
Center for Biomedical Informatics and Information Technology
Career Start Year 1996
Number of shared co-authors 14
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 7
Donald W Parsons
Texas Children's Hospital
Career Start Year 1996
Number of shared co-authors 36
Jaume Mora
Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu
Career Start Year 1996
Number of shared co-authors 28
Kimberly Stegmaier
Dana-Farber Cancer Institute
Career Start Year 1995
Number of shared co-authors 25
Bill H Chang
Oregon Health and Science University
Career Start Year 1993
Number of shared co-authors 3
Olaf Witt
Hopp Children's Cancer Center Heidelberg (KiTZ)
Career Start Year 1993
Number of shared co-authors 23
Jinghui Zhang
Changhai Hospital, Second Military Medical University
Career Start Year 1992
Number of shared co-authors 30
John Easton
St Jude Children's Research Hospital
Career Start Year 1991
Number of shared co-authors 20
Marcel Kool
Hopp Children's Cancer Center (KiTZ)
Career Start Year 1990
Number of shared co-authors 34
Annie Huang
Arthur and Sonia Labatt Brain Tumor Research Centre, Hospital for Sick Children
Career Start Year 1990
Number of shared co-authors 27
Mark W Kieran
Boston Children's Hospital and Harvard Medical School
Career Start Year 1982
Number of shared co-authors 21

Collaborators

John M Maris
Children's Hospital of Philadelphia
Co-authored papers 50
Sharon J Diskin
Children's Hospital of Philadelphia
Co-authored papers 15
Kristina A Cole
Perelman School of Medicine, University of Pennsylvania
Co-authored papers 14
Kateryna Krytska
University of Pennsylvania Perelman School of Medicine
Co-authored papers 13
Elizabeth Fox
Co-authored papers 11
Steven G DuBois
Co-authored papers 9
Hakon Hakonarson
The Center for Applied Genomics, Children's Hospital of Philadelphia
Co-authored papers 9
Malcolm A Smith
National Cancer Institute
Co-authored papers 7
Cecilia E Kim
Co-authored papers 7
Maura Diamond
Co-authored papers 6
Kristopher R Bosse
Co-authored papers 6
Joseph T Glessner
Co-authored papers 6
Rochelle Bagatell
Co-authored papers 6
Esther R Berko
Children's Hospital of Philadelphia.
Co-authored papers 6
Susan L Cohn
Co-authored papers 5
Michael D Hogarty
Co-authored papers 5
Pichai Raman
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Co-authored papers 5
Barbara L Weber
Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania
Co-authored papers 5
Peter J Houghton
The University of Texas Health Science Center at San Antonio
Co-authored papers 4
Daniel Martinez
Perelman School of Medicine at the University of Pennsylvania
Co-authored papers 4
Struan F A Grant
Center for Spatial and Functional Genomics, The Children's Hospital of Philadelphia
Co-authored papers 4
Stephan A Grupp
Co-authored papers 3
Richard Gorlick
University of Texas MD Anderson Cancer Center
Co-authored papers 3
Komal S Rathi
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Co-authored papers 3
Jennifer Pogoriler
Children's Hospital Of Philadelphia
Co-authored papers 3
Nathan M Kendsersky
Perelman School of Medicine, University of Pennsylvania
Co-authored papers 3
Raushan T Kurmasheva
The University of Texas Health Science Center at San Antonio
Co-authored papers 3
Kai Wang
University of Pennsylvania
Co-authored papers 3
Julie M Gastier-Foster
Baylor College of Medicine
Co-authored papers 3
Jonathan P Bradfield
Co-authored papers 3
Release 1.2